nitricoxideby human end othelial cells through activation of thep 38 signal pathway. Zhong hua yi xue za zhi. 2002, 82(19):1328-31.
14. Soro-PaavonenA,ZhangWZ,VenardosK,CoughlanMT,HarrisE,TongDC,BrasacchioD,Paavonen
K,Chin-DustingJ,CooperME,KayeD,ThomasMC,ForbesJM.Advanced glycation end-products induce vascular dysfunction via resistance to nitricoxide and suppression of endothelial nitricoxide synthase.JHypertens.2010Apr;28(4):780-8.
15. NakayamaM,KawaguchiY,YamadaK,etal.Immunohistochemical detection of advanced
glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. KidneyInt,1997;51:182-186.
16. PapayianniA,AlexopoulosE,GiamalisP,GionanlisL,BelechriAM,KoukoudisP,MemmosD(2002)
Circulating level sofICAM-1,VCAM-1,andMCP-1are increase dinhaemodialysis patients:association with inflammation, dyslipidaemia, andvascularevents. Nephrol Dial Transplant17:435–441.
17. PengKF,WuXF,ZhaoHW,SunY(2006)Advanced oxidation protein products induce monocyte
chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells .ChinMedJ(Engl)119:1088–1093.
18. BallowA,GaderAM,HuraibS,Al-HusainiK,MutwalliA,Al-WakeelJ(2005)Platelet surface
receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation.Platelets16:19–24.
19. WautierJL,SchmidtAM(2004)Proteinglycation:a firm link to endothelial cell
dysfunction.CircRes95:233–238.
20. LiJT,HouFF,GuoZJ,ShanYX,ZhangX,LiuZQ.Advanced glycation end products upregulate
C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1beta production.ScandJImmunol.2007 Nov;66(5):555-62.
21. GaribottoG,SofiaA,ProcopioV,VillaggioB,TarroniA,DiMartinoM,CappelliV,GandolfoMT,Alois
iF,DeCianF,SalaMR,VerzolaD(2006)Peripheral tissue release of interleukin-6 inpatients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state. Kidney Int 70:384–390.
22. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P,Salomaa V (2006) Creactiveprotein,
interleukin-6 and tumornecrosis factor alphaaspre dictors of incidentcoronary and cardiovascularevents and to talmortality. Apopulation-based, prospectivestudy. Thromb
5
Haemost 95:511–518.
23. RenH,HouF,BiY,ZhangX.Expression of receptors for advanced glycation end products at
surface of peripheral blood monocytes and relationship thereof to plasma proinflammatory cytokines in patients undergoing hemodialysis. ZhonghuaNeiKeZaZhi. 2002, Jan; 41(1):43-6. 24. Liabeuf,S.;Barreto,D.V.;Barreto,F.C.;Meert,N.;Glorieux,G.;Schepers,E.;Temmar,M.;Choukroun,G.;V
anholder,R.;Massy,Z.A.Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.Nephrol.Dial.Transplant.2010,25,1183–1191.
25. Barreto,F.C.;Barreto,D.V.;Liabeuf,S.;Meert,N.;Glorieux,G.;Temmar,M.;Choukroun,G.;Vanholder,R.;
Massy,Z.A.Serumin doxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.Clin.J.Am.Soc.Nephrol.2009,4,1551–1558.
26. LeeWK,AkyolM,ShawS,DominiczakMH,BriggsJD:Kidney transplantation decreases the tissue
level of advanced glycosylation end products.Nephrol Dial Transplant1995;10:103–107. 27. Wieslander A, Linden T, Mus B, Jarkelid L, Speidel R,BeckW,HenleT, Deppisch
R:Exogenousuptake of carbonyl stress compound spromoting AGE formation from peritoneal dialysisfluids; in D AngeloA,FavaroS,GambaroG(eds):Advanced Glycation End Products in Nephrology.ContribNephrol.Basel,Karger,2001,vol131,pp82–89.
28. ZeierM,DeppischR,HaugU,SchwengerV,HenleT,BahnerU,WannerC,SchneiderH,RitzE:Resorpti
on of AGE-promoting glucose degradation products (GDP) from peritoneal dialysis (PD) fluids leads to increased levels of AGE in plasma.JAmSocNephrol2000;11:223A.
29. KorbetSM,MakitaZ,FiranekCA,VlassaraH:Advance dglycosylation end products in continuous
ambulatory peritoneal dialysis patients.AmJKidneyDis1993;22:588–591.
30. HenleT,DeppischR,BeckW,HergesellO,HanschG,RitzE:Advanced glycated end products (AGE)
during haemodialysis treatment : discrepant results with different methodologies reflecting the heterogenity of AGE compounds.NephrolDialTransplant1999;14:1968–1975.
31. SteinG,FrankeS,MahioutA,SchneiderS,SperschneiderH,BorstS,VienkenJ.Influence of dialysis
modalities on serum AGE levels in end-stage renal disease patients . Nephrol Dial Transplant . 2001May;16(5):999-1008.
32. vanTellingenA,SchalkwijkCG,TeerlinkT,BartoR,GrootemanMP,vanderPloegT,terWeePM,Nubé
MJ.Influence of different haemodialysis modalities on AGE peptide levels : intradialytic versus long-term results.Nephron ClinPract.2005;100(1):c1-7.Epub2005Feb22.
33. MorimotoH,NakaoK,FukuokaK,SaraiA,YanoA,KiharaT,FukudaS,WadaJ,MakinoH.Long-term
6
use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients . Nephrol Dial Transplant.2005Dec;20(12):2775-82.Epub2005Oct12. 34. RenH,HouF,ZhangX.Heparin blocks the binding of advance dglycation end products to its
receptors on human monocytes.ZhonghuaNeiKeZaZhi.2002Jan;41(1):43-6.
35. Kikuchi,K.;Itoh,Y.;Tateoka,R.;Ezawa,A.;Murakami,K.;Niwa,T.Metabolomic search for uremic
toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromato graphy /tandem masss pectrometry.J.Chromatogr.,B:Anal.Technol.Biomed.LifeSci.2010,878,2997–3002. 36. Ueda,H.;Shibahara,N.;Takagi,S.;Inoue,T.;Katsuoka,Y.AST-120 treatment in pre-dialysis period
affects the prognosis in patients on hemodialysis.RenalFail.2008,30,856–860. 37. Nakamura,T.;Kawagoe,Y.;Matsuda,T.;Ueda,Y.;Shimada,N.;Ebihara,I.;Koide,H.Oral
ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure.KidneyBloodPressureRes.2004,27,121–126.
38. Fujii,H.;Nishijima,F.;Goto,S.;Sugano,M.;Yamato,H.;Kitazawa,R.;Kitazawa,S.;Fukagawa,M.Or
al charcoalad sorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol. Dial.Transplant. 2009, 24, 2089–2095. 39. Chen SJ, Jiang GR, Shan JP, Lu W, Huang HD, Ji G, Wu P, Wu GF, Wang W, Zhu C, Bian F.
Combination of maintenance hemodialysis with hemoperfusion: as afeand effective model of artificial kidney. Int J Artif Organs. 2011 Apr; 34(4): 339-47. doi:10.5301/IJAO.2011.7748.
7
相关推荐：
loading